Mirna Therapeutics has appointed Dr Miguel Barbosa as executive vice president and chief scientific officer.
Mirna Therapeutics is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics.
Barbosa joined the company with 20 years of biopharmaceutical research discovery experience and for the past decade has served in senior leadership roles at Johnson & Johnson subsidiaries.
Paul Lammers, Mirna’s president and chief executive officer, said: “We are pleased to welcome Miguel to the role of chief scientific officer.
“As a highly accomplished industry executive with a proven ability to lead top research and development programs, we are confident Miguel’s expertise and strategic vision, particularly in emerging areas of science, will prove critical as we advance our pipeline of microRNA-based oncology therapeutics.”